How Wall Street Analysts View Ventas
Analyst ratings for Ventas (VTR) reflect its performance expectations for 2018. Analysts gave VTR a mean price target of $62.25, implying a ~11.2% rise from its current level of $55.97. It has a market capitalization of about $19.5 billion.
As of January 2018, two of 20 analysts covering the stock gave it “buy” or “strong buy” ratings, 14 gave it a “hold” rating, and the remaining four gave it a “sell” rating. The number of Ventas’s “strong buy” and “buy” ratings are consistent with December 2017.
Interested in HCN? Don't miss the next report.
Receive e-mail alerts for new research on HCN
VTR’s peer ratings
Among Ventas’s major alternative peers, Welltower (HCN) got a “buy” or “strong buy” rating from five of 22 analysts and a “hold” rating from 14 analysts. It got a “sell” rating from the remaining three analysts. The target price for HCN is $68.86, while the current price is $59.97.
Four of 20 analysts gave HCP (HCP) a “buy” or “strong buy” rating, 15 analysts gave it a “hold” rating, and the remaining one analyst gave it a “sell” rating. The target price for HCP is $27.78 compared to the current level of $24.08.
Ten of 12 analysts gave the Healthcare Trust of America (HTA) a “buy” or “strong buy” rating, while the remaining two gave it a “hold” rating. The target price for HTA is $33.63 compared to the current level of $27.61.
Investors looking for exposure to the healthcare real estate sector can invest in REIT ETFs. VTR forms 2.4% of the iShares Core U.S. REIT ETF (USRT).